A subset of CPP member organizations* have convened to collaborate precompetitively with the goal of optimizing the efficiency of paths for developing digital tools for PD drug development. 3DT is leveraging a prospective study called WATCH-PD (Wearable Assessments in The Clinic and Home in PD), a 12-month multi-center, longitudinal, digital assessment study of PD progression in subjects with early, untreated PD as an exemplar pilot study to collect digital data in an early PD target population for the purpose of facilitating discussion and alignment with regulatory agencies.